Tenax Common Stock Total Equity vs Cash And Short Term Investments Analysis

TENX Stock  USD 6.01  0.07  1.18%   
Tenax Therapeutics financial indicator trend analysis is much more than just breaking down Tenax Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tenax Therapeutics is a good investment. Please check the relationship between Tenax Therapeutics Common Stock Total Equity and its Cash And Short Term Investments accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenax Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.

Common Stock Total Equity vs Cash And Short Term Investments

Common Stock Total Equity vs Cash And Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tenax Therapeutics Common Stock Total Equity account and Cash And Short Term Investments. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Tenax Therapeutics' Common Stock Total Equity and Cash And Short Term Investments is -0.21. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Tenax Therapeutics, assuming nothing else is changed. The correlation between historical values of Tenax Therapeutics' Common Stock Total Equity and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of Tenax Therapeutics are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Common Stock Total Equity i.e., Tenax Therapeutics' Common Stock Total Equity and Cash And Short Term Investments go up and down completely randomly.

Correlation Coefficient

-0.21
Relationship DirectionNegative 
Relationship StrengthInsignificant

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Tenax Therapeutics balance sheet. This account contains Tenax Therapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Tenax Therapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.
Most indicators from Tenax Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tenax Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenax Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.At this time, Tenax Therapeutics' Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 0.49 in 2024, whereas Selling General Administrative is likely to drop slightly above 4.9 M in 2024.
 2021 2022 2023 2024 (projected)
Other Operating Expenses32.7M11.1M8.2M8.4M
Depreciation And Amortization109.0K113.3K7.6K7.2K

Tenax Therapeutics fundamental ratios Correlations

-0.220.190.131.0-0.17-0.990.27-0.140.990.761.00.340.91-0.130.110.891.00.26-0.19-0.19-0.2-0.53-0.390.02-0.31
-0.22-0.04-0.04-0.260.720.280.33-0.03-0.23-0.13-0.25-0.20.17-0.17-0.430.16-0.25-0.22-0.1-0.10.730.090.35-0.160.56
0.19-0.040.830.16-0.2-0.140.05-0.130.140.330.16-0.070.11-0.170.010.380.16-0.17-0.18-0.18-0.18-0.06-0.350.05-0.06
0.13-0.040.830.11-0.29-0.1-0.190.360.10.160.10.30.010.310.250.340.11-0.03-0.33-0.33-0.230.02-0.27-0.160.02
1.0-0.260.160.11-0.2-1.00.25-0.140.990.761.00.340.9-0.120.130.871.00.27-0.18-0.18-0.23-0.53-0.40.03-0.33
-0.170.72-0.2-0.29-0.20.20.46-0.31-0.17-0.07-0.2-0.260.17-0.47-0.560.11-0.2-0.220.140.140.980.030.520.080.6
-0.990.28-0.14-0.1-1.00.2-0.220.1-1.0-0.74-1.0-0.36-0.880.09-0.16-0.85-1.0-0.280.190.190.240.520.39-0.010.34
0.270.330.05-0.190.250.46-0.22-0.530.240.280.23-0.190.47-0.62-0.930.390.23-0.270.60.60.37-0.180.270.670.45
-0.14-0.03-0.130.36-0.14-0.310.1-0.53-0.11-0.38-0.120.74-0.240.820.52-0.11-0.110.05-0.31-0.3-0.220.23-0.05-0.42-0.19
0.99-0.230.140.10.99-0.17-1.00.24-0.110.751.00.350.91-0.10.130.871.00.27-0.19-0.19-0.2-0.53-0.370.01-0.32
0.76-0.130.330.160.76-0.07-0.740.28-0.380.750.75-0.180.71-0.270.00.720.750.16-0.12-0.12-0.14-0.66-0.370.17-0.19
1.0-0.250.160.11.0-0.2-1.00.23-0.121.00.750.340.9-0.120.140.871.00.26-0.21-0.21-0.23-0.53-0.410.0-0.34
0.34-0.2-0.070.30.34-0.26-0.36-0.190.740.35-0.180.340.20.570.340.290.350.21-0.18-0.18-0.20.05-0.14-0.23-0.28
0.910.170.110.010.90.17-0.880.47-0.240.910.710.90.2-0.31-0.140.940.90.12-0.18-0.180.14-0.5-0.250.0-0.06
-0.13-0.17-0.170.31-0.12-0.470.09-0.620.82-0.1-0.27-0.120.57-0.310.62-0.19-0.10.51-0.23-0.22-0.390.150.08-0.31-0.26
0.11-0.430.010.250.13-0.56-0.16-0.930.520.130.00.140.34-0.140.62-0.070.150.37-0.68-0.68-0.48-0.02-0.42-0.67-0.58
0.890.160.380.340.870.11-0.850.39-0.110.870.720.870.290.94-0.19-0.070.870.13-0.27-0.270.09-0.46-0.29-0.04-0.02
1.0-0.250.160.111.0-0.2-1.00.23-0.111.00.751.00.350.9-0.10.150.870.27-0.21-0.21-0.23-0.52-0.41-0.01-0.34
0.26-0.22-0.17-0.030.27-0.22-0.28-0.270.050.270.160.260.210.120.510.370.130.270.040.03-0.23-0.160.270.05-0.36
-0.19-0.1-0.18-0.33-0.180.140.190.6-0.31-0.19-0.12-0.21-0.18-0.18-0.23-0.68-0.27-0.210.041.00.030.060.630.950.06
-0.19-0.1-0.18-0.33-0.180.140.190.6-0.3-0.19-0.12-0.21-0.18-0.18-0.22-0.68-0.27-0.210.031.00.030.060.620.950.06
-0.20.73-0.18-0.23-0.230.980.240.37-0.22-0.2-0.14-0.23-0.20.14-0.39-0.480.09-0.23-0.230.030.030.150.48-0.040.61
-0.530.09-0.060.02-0.530.030.52-0.180.23-0.53-0.66-0.530.05-0.50.15-0.02-0.46-0.52-0.160.060.060.150.22-0.10.14
-0.390.35-0.35-0.27-0.40.520.390.27-0.05-0.37-0.37-0.41-0.14-0.250.08-0.42-0.29-0.410.270.630.620.480.220.480.31
0.02-0.160.05-0.160.030.08-0.010.67-0.420.010.170.0-0.230.0-0.31-0.67-0.04-0.010.050.950.95-0.04-0.10.480.0
-0.310.56-0.060.02-0.330.60.340.45-0.19-0.32-0.19-0.34-0.28-0.06-0.26-0.58-0.02-0.34-0.360.060.060.610.140.310.0
Click cells to compare fundamentals

Tenax Therapeutics Account Relationship Matchups

Tenax Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets6.4M6.9M6.0M3.4M11.7M15.5M
Other Current Liab760.0K1.2M597.1K655.7K1.0M790.7K
Total Current Liabilities2.5M2.1M1.6M1.8M3.6M3.8M
Total Stockholder Equity3.8M4.6M4.2M1.5M8.1M12.7M
Property Plant And Equipment Net8.5K176.0K64.8K294.8K186.7K0.0
Net Debt(4.7M)(5.9M)(5.3M)(1.3M)(9.3M)(9.8M)
Retained Earnings(236.2M)(246.0M)(278.5M)(289.5M)(297.3M)(282.4M)
Accounts Payable1.7M757.9K859.6K448.4K2.1M2.2M
Cash4.9M6.3M5.6M2.1M9.8M9.6M
Non Current Assets Total184.4K73.2K303.2K196.2K1.1K1.1K
Cash And Short Term Investments5.4M6.7M5.6M2.1M9.8M10.0M
Common Stock Shares Outstanding309.8K6.5K12.9K18.4K248.4K260.9K
Liabilities And Stockholders Equity6.4M6.9M6.0M3.4M11.7M15.5M
Non Current Liabilities Total749.8K60.4K124.2K183.6K64.2K0.0
Other Current Assets781.0K82.6K105.1K1.1M1.9M2.0M
Other Stockholder Equity239.9M250.6M282.7M291.0M305.4M320.6M
Total Liab2.6M2.2M1.7M1.9M3.6M2.8M
Total Current Assets6.2M6.8M5.7M3.2M11.7M10.5M
Common Stock674.01.3K2.5K4.6K30.028.5
Common Stock Total Equity141.0379.0674.01.3K1.1K1.1K
Property Plant And Equipment Gross8.5K176.0K6.0K294.8K186.7K0.0
Accumulated Other Comprehensive Income(16.2K)516.0458.0(70.0)(63.0)(66.15)
Property Plant Equipment8.5K6.6K64.8K294.8K265.3K172.3K
Net Tangible Assets11.8M3.8M4.6M4.2M3.8M3.6M
Retained Earnings Total Equity(213.5M)(227.8M)(236.2M)(246.0M)(221.4M)(232.5M)
Capital Surpluse222.4M239.6M239.9M250.6M288.2M226.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Tenax Stock Analysis

When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.